Cantor Fitzgerald analyst William Tanner believes some investors connected two of his prior comments about TherapeuticsMD disclosing ongoing labeling talks with the FDA regarding TX-001 and his foreseeing that the company would need to raise capital in the future and "jumped to" the conclusion that the company would raise capital after TX-001 approval, assuming that occurs. However, in an updated corporate presentation, the company noted a cash balance of $154.4M at the end of Q2 and Tanner projects cash of about $70M at the end of 2019 before the company becomes cash flow positive in the beginning of 2020. Tanner also noted that management has explained that their labeling talks disclosure was meant to take the topic off the table and prevent "awkward conversations" at Cantor's healthcare conference. The analyst, who now believes he was "dead wrong" in his assumption that the FDA talks disclosure may have been made to get "the stock moving," reiterates an Overweight rating and $27 price target on TherapeuticsMD shares.